PPAR, P53, IL6, IL2, hypoxia, Huntington’s disease, TLR and cell cycle were the pathways more significantly modified in the the IPA analysis of our data, when P39 was co-incubated with bortezomib/ATO. This evidence concerns the gene IL2 and Huntington disease.